20-075 Phase I
A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (View details on clinicaltrial.gov)
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (View details on clinicaltrial.gov)
A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients with Metastatic Castration-Resistant Prostate Cancer (View details on clinicaltrial.gov)
A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy (View details on clinicaltrial.gov)
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer (View details on clinicaltrial.gov)
A Phase 1/2, open-label, dose escalation and cohort expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration-resistant prostate cancer (View details on clinicaltrial.gov)
A Phase 2 Study of PCM-075 in Combination with Abiraterone and Prednisone in Subjects with Metastatic Castration-Resistant Prostate Cancer (View details on clinicaltrial.gov)
A PROSPECTIVE COMPARATIVE STUDY OF OUTCOMES WITH PROTON AND PHOTON RADIATION IN PROSTATE CANCER (COMPPARE) (View details on clinicaltrial.gov)
Circulating Tumor Cell Analysis in Patients with Localized Prostate Cancer Undergoing Prostatectomy (View details on clinicaltrial.gov)
Continuing Access to the Tyrosine Kinase Inhibitor Of VEGFR-2, AG-013736 (A406) For Patients Previously Receiving AG-013736 In Clinical Trials (View details on clinicaltrial.gov)
NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*) (View details on clinicaltrial.gov)